Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin-American cohort of 212 patients

Am J Hematol. 2020 Dec;95(12):E323-E326. doi: 10.1002/ajh.25987. Epub 2020 Oct 1.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Aged
  • Azacitidine* / administration & dosage
  • Azacitidine* / adverse effects
  • Databases, Factual*
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Humans
  • Latin America / epidemiology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / mortality
  • Retrospective Studies
  • Severity of Illness Index
  • Survival Rate
  • Thrombocytopenia / blood
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / mortality

Substances

  • Azacitidine